Evidence map›Paper›PMID 40447347›Full record

ArticleThe Lancet. Haematology2025

Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series.

Gita Thanarajasingam, Ajay Major, Vishal Bhatnagar, Amylou C Dueck, Karin E Smedby, Tarec Christoffer El-Galaly, Jan Geissler, Thomas Habermann, Paul G Kluetz, John F Seymour and 3 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Lancet. Haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Gita ThanarajasingamDivision of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: Thanarajasingam.Gita@mayo.edu.
Ajay MajorDivision of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Vishal BhatnagarUnited States Food and Drug Administration, Silver Spring, MD, USA.
Amylou C DueckDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Karin E SmedbyDivision of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Tarec Christoffer El-GalalyDepartment of Clinical Epidemiology, Department of Molecular Medicine and Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Jan GeisslerPatvocates, Munich, Germany.
Thomas HabermannDivision of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Paul G KluetzUnited States Food and Drug Administration, Silver Spring, MD, USA.
John F SeymourDepartment of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia.
Kyriaki TzoganiOrphans Medicine Office, European Medicines Agency, Amsterdam, Netherlands.
Diego VillaBC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada.
Paul J BröckelmannDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40447347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.